A double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.

Trial Profile

A double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs ATL 1102 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 09 Sep 2015 Results published in Antisense Therapeutics media release.
    • 22 Sep 2014 Trial results published in the medical journal Neurology, as reported in an Antisense Therapeutics media release.
    • 25 Sep 2013 Results from this trial will be completed and submitted to a peer-reviewed scientific journal for publication in the fourth quarter of 2013 according to an Antisense Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top